Can Viking Therapeutics cover its short-term obligations?

Its current ratio is 5.72 — current assets exceed current liabilities.

Where does Viking Therapeutics's balance sheet data come from?

Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Viking Therapeutics VKTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$118.12M-28.8%	$165.81M+65.2%	$100.38M+196%	$33.88M-10.7%	$37.94M+42.2%
Short-term investments	$484.85M-10.2%	$539.93M-12.1%	$614.19M-20.6%	$773.84M-4.9%	$813.92M-7.1%
Prepaid expenses and other current assets	$1.22M-32.2%	$1.81M-19.4%	$2.24M-20.4%	$2.82M+225%	$865K-23.3%
Total current assets	$608.21M-15.0%	$715.6M-3.1%	$738.7M-10.7%	$827.02M-4.5%	$866.02M-4.5%
Operating lease right-of-use assets	$0-100%	$85K-87.2%	$666K-14.6%	$780K-12.6%	$892K-11.1%
Other non-current assets	$33K-28.3%	$46K0.0%	$46K0.0%	$46K0.0%	$46K0.0%
Total assets	$608.24M-15.0%	$715.73M-3.2%	$739.42M-10.7%	$827.85M-4.5%	$866.99M-4.5%
Accounts payable	$67.18M+26.2%	$53.25M+1,107%	$4.41M-19.7%	$5.49M-28.7%	$7.7M-21.5%
Accrued expenses	$39.14M+68.1%	$23.28M+9.7%	$21.22M-18.5%	$26.02M+129%	$11.37M-33.5%
Operating lease liabilities, current	$0-100%	$137K-68.6%	$437K-6.6%	$468K-6.0%	$498K+1.8%
Total current liabilities	$106.33M+38.7%	$76.67M+194%	$26.07M-18.5%	$31.98M+63.4%	$19.57M-28.6%
Operating Lease Liabilities (Total)	$0-100%	$137K-81.9%	$755K-14.0%	$878K-12.2%	$1M-10.6%
Total liabilities	$106.33M+38.7%	$76.67M+191%	$26.39M-18.5%	$32.39M+61.3%	$20.08M-28.4%
Common stock	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%
Additional paid-in capital	$1.51B+1.5%	$1.49B+6.0%	$1.4B+0.6%	$1.39B+1.0%	$1.38B+0.9%
Retained earnings	-$1.01B-18.7%	-$847.55M-22.9%	-$689.88M-15.2%	-$599.1M-12.3%	-$533.54M-9.4%
Accumulated other comprehensive income (loss)	-$856K-326%	$378K+1.1%	$374K+325%	-$166K+23.1%	-$216K+72.6%
Treasury stock	——	$0—	$0—	$0—	$0—
Total stockholders' equity	$501.92M-21.5%	$639.06M-10.4%	$713.03M-10.4%	$795.46M-6.1%	$846.92M-3.8%
Total liabilities and stockholders' equity	$608.24M-15.0%	$715.73M-3.2%	$739.42M-10.7%	$827.85M-4.5%	$866.99M-4.5%
Available For Sale Securities Debt Securities Current	$484.85M-10.2%	$539.93M-12.1%	$614.19M-20.6%	$773.84M-4.9%	$813.92M-7.1%
Prepaid Clinical Trial And Preclinical Study Costs	$4.02M-50.1%	$8.05M-63.2%	$21.89M+32.8%	$16.48M+23.9%	$13.3M+283%
Deposits on Licenses	$33K-28.3%	$46K0.0%	$46K0.0%	$46K0.0%	$46K0.0%
Net Investment in Lease	$0-100%	$85K-87.2%	$666K-14.6%	$780K-12.6%	$892K-11.1%
Operating lease right-of-use assets	$0-100%	$85K-87.2%	$666K-14.6%	$780K-12.6%	$892K-11.1%
Operating Lease Right-of-Use Assets in Other Assets	$0-100%	$85K-87.2%	$666K-14.6%	$780K-12.6%	$892K-11.1%
Total debt	——	$137K-81.9%	$755K-14.0%	$878K-12.2%	$1M-10.6%
AOCI - Available-for-Sale Securities, Net of Tax	-$856K-326%	$378K+1.1%	$374K+325%	-$166K+23.1%	-$216K+72.6%
Additional paid-in capital	$1.51B+1.5%	$1.49B+6.0%	$1.4B+0.6%	$1.39B+1.0%	$1.38B+0.9%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%
Other accrued liabilities	$39.14M+68.1%	$23.28M+9.7%	$21.22M-18.5%	$26.02M+129%	$11.37M-33.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Viking Therapeutics cover its short-term obligations?: Its current ratio is 5.72 — current assets exceed current liabilities.
Where does Viking Therapeutics's balance sheet data come from?: Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.